Mission & Aims
PANAXEA is a University of Twente spin-off accelerating patient access to biomedical innovations by building scientific evidence to inform strategic development, pricing and reimbursement decisions. Panaxea’s mission is to accelerate market access and reimbursement for healthcare innovations with added value to the individual patient, the healthcare system and ultimately society. It does so by applying and developing innovative scientific methodologies for Value-Based Reimbursement Analysis and Health Technology Assessment specifically for medical products in an early stage of development (i.e. before large scale clinical studies have been done). Notably, its founders have laid the academic groundwork for this “early-stage” analysis approach that is now used worldwide by health economists, healthcare decision makers and innovative industries.
We combine health economic, health science and strategic expertise to provide a range of services that helps identifying, building and articulating the clinical, humanistic and economic value of your product to inform local, national and international decisions makers.
- Mantjes G, Steuten L. Economic value of procalcitonin guidance. Lancet Infectious Diseases 2016;16:1000
- Plun-Favreau J, Immonen-Charalambous K, Steuten L, Strootker A, Rouzier R, Horgan D, Lawler M. Enabling Equal Access to Molecular Diagnostics: What Are the Implications for Policy and Health Technology Assessment. Public Health Genomics. 2016 Jun 1;19(3):144-152. [Epub ahead of print]
- Steuten LM. Early Stage Health Technology Assessment for Precision Biomarkers in Oral Health and Systems Medicine. 2016 Jan;20(1):30-35.
- Oosterhoff M, van der Maas ME, Steuten LM. A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers. Appl Health Econ Health Policy 2016 Feb;14(1):51-65]
- Lepage-Nefkens I, Van der Maas M, Rijnen M, Hermansson L. A Cost-Effectiveness Model Evaluating Component-Resolved Diagnosis (Crd) Versus Standard Testing Method (Skin Prick Testing (Spt)) In The Diagnosis And Treatment of Allergic Rhinitis In The Netherlands. Value Health. 2015 Nov;18(7):A359.
- Kip M, van dB, Fischer K, Tamminga R, Lepage-Nefkens I. Cost Effectiveness Analysis Evaluating Factor Viii As Primary Prophylaxis Treatment for Patients With Severe Haemophilia A In the Netherlands. Value Health. 2014 Nov;17(7):A531.
- Van der Maas M, Lepage-Nefkens I, de Graaf G. Development Of A Model To Provide Insight In The Value Of Fibrinogen Concentrate For Treating Excessive Bleedings During Complex Cardiovascular Surgery. Value Health. 2015 Nov;18(7):A391.
- De Graaf G, Steuten L, Pecchia L, Boehler C. Early Health Economic Assessment in Innovation Partnerships: Lessons from the European Innovation Partnership on Active and Healthy Ageing. Value Health. 2015 Nov;18(7):A726.
- Farfan-Portet MI, Gerkens S, Lepage-Nefkens I, Vinck I, Hulstaert F. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ. 2014 Apr;15(3):223-8.
- Steuten LM, Ramsey SD. Improving early cycle economic evaluation of diagnostic technologies. Expert Rev Pharmacoecon Outcomes Res. 2014 Aug;14(4):491-8.
- Van de Wetering G, Steuten LMG, Von Birgelen C, IJzerman MJ. Early Bayesian modelling of a potassium lab-on-a-chip for monitoring of heart failure patients at increased risk of hyperkalaemia. Technological Forecasting and Social Change 2012;79(7):1268-79.
- Postmus D, de Graaf G, Hillege HL, Steyerberg EW, Buskens E. A method for the early health technology assessment of novel biomarker measurement in primary prevention programs. Stat Med. 2012 Oct 15;31(23):2733-44.
- Ijzerman MJ, Steuten LM. Early assessment of medical technologies to inform product development and market access: a review of methods and applications. Appl Health Econ Health Policy. 2011 Sep 1;9(5):331-47. Vrijhoef HJ, Diederiks JP, Wesseling GJ, van Schayck CP, Spreeuwenberg C. Undiagnosed patients and patients at risk for COPD in primary health care: early detection with the support of non-physicians. J Clin Nurs. 2003 May;12(3):366-73.